- Lenalidomide+obinutuzumab induction and maintenance was well tolerated and effective in relapsed/refractory follicular lymphoma, even among patients with early relapse.
Why this matters
- Patients in this study had no other efficacious treatment options.
- Phase 2 study to investigate obinutuzumab+lenalidomide induction and maintenance in patients with relapsed/refractory follicular lymphoma.
- 89 patients were recruited; 88 patients were in the safety population; 86 patients were evaluable for efficacy.
- Patients had received ≥1 prior rituximab-containing regimen.
- 27% of patients had experienced early disease progression (within ≤24 months of initial diagnosis).
- Funding: Lymphoma Academic Research Organisation; Celgene; Roche.
- Best response during induction: 81% (95% CI, 72%-89%).
- Response at end of induction: 79% (95% CI, 69%-87%).
- Best response during treatment: 84% (95% CI, 74%-91%).
- Complete response: 27%.
- Complete unconfirmed response: 12%.
- Partial response: 41%.
- In post hoc analysis, overall responses were numerically comparable in patients with early vs later relapse.
- 2-year outcomes:
- PFS: 65% (95% CI, 54%-74%).
- OS: 87% (95% CI, 78%-93%).
- Duration of response: 70% (95% CI, 57%-79%).
- Most common grade 3-4 adverse event included: neutropenia (43%), thrombocytopenia (14%).
- No central radiology review.